SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of matters to a vote of Security Holders. |
At the 2017 Annual Meeting of Stockholders of the Company held on
June8, 2017 (the Annual Meeting), the matters on which the
stockholders voted, in person or by proxy were:
| (i) |
To elect six nominees as directors to serve until the next Annual Meeting and until their successors have been elected and qualified; |
| (ii) |
To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys Proxy Statement; |
| (iii) |
To approve, on an advisory basis, the frequency of future advisory votes on Companys named executive officer compensation; |
| (iv) |
To ratify the selection of PricewaterhouseCoopers Zhong Tian LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017; and |
| (v) |
To vote upon a stockholder proposal relating to proxy access, if properly presented at the Annual Meeting. |
The six nominees were elected, the compensation of named
executive officers was approved (on an advisory basis), the
frequency for future advisory votes on Companys named executive
officers compensation was approved, the appointment of the
independent registered public accounting firm was ratified, and
the stockholder proposal to amend proxy access was not approved
and failed. The results of the voting were as follows:
|
Election of Directors |
VotesFor | VotesWithheld | BrokerNon-votes | |||
|
Jon S. Saxe |
33,897,004 | 813,013 | 5,554,296 | |||
|
Friedhelm Blobel, Ph.D. |
34,299,422 | 410,595 | 5,554,296 | |||
|
Nancy T. Chang, Ph.D. |
33,903,476 | 806,541 | 5,554,296 | |||
|
Richard J. Hawkins |
31,268,488 | 3,441,529 | 5,554,296 | |||
|
Gregg A. Lapointe |
34,178,410 | 531,607 | 5,554,296 | |||
|
Simon Li |
33,903,289 | 806,728 | 5,554,296 |
| VotesFor | VotesAgainst | Abstentions | BrokerNon-votes | |||||
|
Approval of Executive Compensation |
33,121,822 | 1,326,662 | 261,533 | 5,554,296 |
| 1Year | 2Years | 3Years | Abstentions | BrokerNon-votes | ||||||
|
Approval of Frequency of Advisory Vote |
24,412,463 | 41,073 | 10,000,523 | 255,958 | 5,554,296 |
| VotesFor | VotesAgainst | Abstentions | ||||
|
Approval of independent registered public accounting firm |
39,928,835 | 61,668 | 273,810 |
| VotesFor | VotesAgainst | Abstentions | BrokerNon-votes | |||||
|
Approval of shareholder proposal to amend proxy access |
9,624,383 | 24,413,019 | 672,615 | 5,554,296 |
About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).
